In Q1 2023, Casdin Capital held 31 positions worth $1.0B. They initiated 31 new positions. Their largest holding was BLFS ($164.7M).
Frequently asked questions
What stocks did Casdin Capital own in Q1 2023?
Casdin Capital held 31 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include BLFS, SRPT, RLAY, ILMN, ALNY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Casdin Capital's portfolio worth in Q1 2023?
Casdin Capital's tracked biotech portfolio was worth $1.0B across 31 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Casdin Capital buy in Q1 2023?
Casdin Capital initiated 31 new positions in Q1 2023, including BLFS, SRPT, RLAY, ILMN, ALNY and 26 more. They also increased 0 existing positions.
What did Casdin Capital sell in Q1 2023?
Casdin Capital did not fully exit any positions in Q1 2023.
Is Casdin Capital a biotech fund?
Life sciences tools and genomics specialist. Casdin Capital focuses on the "picks and shovels" of biotech—sequencing platforms, diagnostics companies, and enabling technologies—rather than traditional drug development bets. Known for early conviction in the genomics revolution.
Want AI analysis, insider signals, and catalyst overlays for Casdin Capital?
View latest Casdin Capital portfolio →